Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PIT 565

Next Previous
X
Search
Drug Profile

PIT 565

Alternative Names: PIT-565

Latest Information Update: 02 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis Pharmaceuticals
  • Class Antineoplastics; Immunotherapies; Trispecific antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 28 Mar 2024 Novartis Pharmaceuticals plans a phase Ib trial for Systemic lupus erythematosus (Treatment-experienced) (SC) (NCT06335979)
  • 10 Dec 2022 Updated pharmacodynamics data from a preclinical trial in Non-Hodgkin's lymphoma presented at 64th American Society of Hematology Annual Meeting and Exposition 2022 (ASH-Hem-2022)
  • 12 Sep 2022 Phase-I clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater) in Israel (IV) (NCT05397496)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top